Viking Therapeutics Inc (NASDAQ:VKTX)
| 5.39 Delayed Data As of Nov 26 |  -0.28 / -4.94%Today’s Change | 4.95 Today|||52-Week Range 10.09 | -4.26% Year-to-Date |
Latest VKTX News | Press Releases
| Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis Nov 24 / Zacks.com - Paid Partner Content | Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA Nov 22 / Zacks.com - Paid Partner Content |
| Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU Nov 22 / Zacks.com - Paid Partner Content | Wall Street Analysts Think Viking Therapeutics, Inc. (VKTX) Could Surge 226%: Read This Before Placing a Bet Nov 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.67 |
| Today’s open | 5.57 |
| Day’s range | 5.34 - 5.65 |
| Volume | 21,010 |
| Average volume (3 months) | 613,347 |
| Market cap | $421.7M |
Data as of 1:00pm ET, 11/26/2021
Growth & Valuation
| Earnings growth (last year) | -51.87% |
| Earnings growth (this year) | -36.70% |
| Earnings growth (next 5 years) | +40.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.62 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ABUSArbutus Biopharma Co... | -0.06 | -1.72% |
| ZOMZomedica Corp | -0.01 | -2.37% |
| TCDATricida Inc | -0.28 | -3.64% |
| CLVSClovis Oncology Inc | -0.12 | -3.59% |
Data as of 1:00pm ET, 11/26/2021
Financials
| Next reporting date | March 9, 2022 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$39.5M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
